Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.

Benekli M, Yildiz R, Uner A, Er O, Yamac D, Alkis N, Coskun U, Camci C, Buyukberber S.

Oncology. 2007;72(5-6):308-13. doi: 10.1159/000113053. Epub 2008 Jan 14.

PMID:
18198492
[PubMed - indexed for MEDLINE]
2.

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.

Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, Boeck HP, Schmid B, Kettner E, Stauch M, Lordick F, Ko Y, Geissler M, Schoppmeyer K, Kojouharoff G, Golf A, Neugebauer S, Heinemann V.

Ann Oncol. 2008 Feb;19(2):340-7. Epub 2007 Oct 24.

PMID:
17962204
[PubMed - indexed for MEDLINE]
Free Article
3.

Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.

Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ.

Cancer. 2007 Sep 15;110(6):1307-12.

PMID:
17628484
[PubMed - indexed for MEDLINE]
Free Article
4.

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group.

J Clin Oncol. 2007 Jun 1;25(16):2212-7.

PMID:
17538165
[PubMed - indexed for MEDLINE]
Free Article
5.

A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.

Park BB, Park JO, Lee HR, Lee J, Choi DW, Choi SH, Heo JS, Lee JK, Lee KT, Lim do H, Park YS, Lim HY, Kang WK, Park K.

Cancer Chemother Pharmacol. 2007 Sep;60(4):489-94. Epub 2007 Mar 30.

PMID:
17396266
[PubMed - indexed for MEDLINE]
6.

A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.

Santini D, Virzí V, Vincenzi B, Rocci L, Leoni V, Tonini G.

Ann Oncol. 2007 Mar;18(3):576-80. Epub 2006 Dec 8.

PMID:
17158771
[PubMed - indexed for MEDLINE]
Free Article
7.

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.

Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ; Cancer and Leukemia Group B.

Cancer. 2006 Sep 15;107(6):1273-9.

PMID:
16909426
[PubMed - indexed for MEDLINE]
Free Article
8.

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ.

J Clin Oncol. 2005 Apr 1;23(10):2332-8.

PMID:
15800324
[PubMed - indexed for MEDLINE]
Free Article
9.

A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.

Rini BI, Weinberg V, Small EJ.

Cancer. 2005 Feb 1;103(3):553-8.

PMID:
15612026
[PubMed - indexed for MEDLINE]
Free Article
10.

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.

Waters JS, Moss C, Pyle L, James M, Hackett S, A'hern R, Gore M, Eisen T.

Br J Cancer. 2004 Nov 15;91(10):1763-8.

PMID:
15505625
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J.

J Clin Oncol. 2003 Sep 15;21(18):3402-8. Epub 2003 Jul 28.

PMID:
12885837
[PubMed - indexed for MEDLINE]
12.

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.

Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R.

J Clin Oncol. 2003 Jan 1;21(1):66-8.

PMID:
12506172
[PubMed - indexed for MEDLINE]
13.

Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.

Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ.

J Clin Oncol. 2002 Jan 15;20(2):582-7.

PMID:
11786589
[PubMed - indexed for MEDLINE]
14.

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.

Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B.

Cancer Chemother Pharmacol. 2000;45(4):291-7.

PMID:
10755317
[PubMed - indexed for MEDLINE]
15.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.

PMID:
10655437
[PubMed - indexed for MEDLINE]
Free Article
16.

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H.

Eur J Cancer. 1998 Jul;34(8):1274-81.

PMID:
9849491
[PubMed - indexed for MEDLINE]
17.

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J.

J Clin Oncol. 1998 Sep;16(9):2977-85.

PMID:
9738566
[PubMed - indexed for MEDLINE]
18.

Accelerated titration designs for phase I clinical trials in oncology.

Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC.

J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47.

PMID:
9262252
[PubMed - indexed for MEDLINE]
Free Article
19.

Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP.

Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.

PMID:
7165009
[PubMed - indexed for MEDLINE]
20.

Design and analysis of phase I clinical trials.

Storer BE.

Biometrics. 1989 Sep;45(3):925-37.

PMID:
2790129
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk